Buscar en
Farmacia Hospitalaria (English Edition)
Toda la web
Inicio Farmacia Hospitalaria (English Edition) Drug interactions of new antiretroviral drugs
Información de la revista
Vol. 35. Núm. 1.
Páginas 36-43 (Enero 2011)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 35. Núm. 1.
Páginas 36-43 (Enero 2011)
Review
Acceso a texto completo
Drug interactions of new antiretroviral drugs
Interacciones farmacológicas de los nuevos antirretrovirales
Visitas
...
J.I. Serrano López de las Hazas
Servicio de Farmacia, Hospital Son Llátzer, Palma de Mallorca, Spain
Información del artículo
Resumen
Bibliografía
Descargar PDF
Estadísticas
Abstract

A systematic review was made of the drug interactions of new antiretroviral drugs. In order to do this a search was made in Pubmed to find articles published from January 2007 to September 2009 and the full-text articles which contained information about new antiretroviral drugs were selected. This search was then complemented with information from the technical specifications of the drugs and consultations made on webpages specialized in antiretroviral interactions: www.interaccioneshiv.com and www.hiv-druginteractions.org. The information about the possible interactions of new antiretroviral drugs with one another and with the therapeutic groups which are most widely used in patients infected with the human immunodeficiency virus was analyzed.

Keywords:
Systematic review
Antiretroviral therapy
Drug interactions
Darunavir
Etravirine
Maraviroc
Raltegravir
Resumen

Se realiza una revisión sistemática sobre interacciones medicamentosas de los nuevos fármacos antirretrovirales. Para ello se realiza una búsqueda en Pubmed de artículos publicados entre enero de 2007 y septiembre de 2009 y se consideraron los artículos disponibles a texto completo que aportaban alguna información sobre los nuevos antirretrovirales. Esta búsqueda fue complementada a su vez con la información de las fichas técnicas de los productos y consultas en las páginas web específicas de interacciones de antirretrovirales: www.interaccioneshiv. com y www.hiv-druginteractions.org. Se analiza la información de las posibles interacciones de los nuevos antirretrovirales entre sí, y con los grupos terapéuticos más frecuentemente utilizados en pacientes con el virus de la inmunodeficiencia humana.

Palabras clave:
Revisión sistemática
Terapia antirretroviral
Interacciones medicamentosas
Darunavir
Etravirina
Maraviroc
Raltegravir
El Texto completo está disponible en PDF
References
[1.]
K. Seden, D. Back, S. Khoo.
Antiretroviral drug interactions: often unrecognized, frequently unavoidable, sometimes unmanageable.
J Antimicrob Chemother, 64 (2009), pp. 5-8
[2.]
M.M. De Maat, A. De Boer, C.H. Koks, J.W. Mulder, P.L. Meenhorst, E.C. Van Gorp, et al.
Evaluation of clinical pharmacist interventions on drug interactions in outpatient pharmaceutical HIV-care.
J Clin Pharm Ther, 29 (2004), pp. 121-130
[3.]
S. Shah, J. McGowan, B. Opulski, A. Lieblein, A. Saperstein.
Identification of Drug Interactions Involving ART in New York City HIV Specialty Clinics.
CROI; Poster, (2007),
[4.]
S.H. Khoo.
O121 Drug interactions that really matter. University of Liverpool, Liverpool, UK from Ninth International Congress on Drug Therapy in HIV Infection Glasgow, UK 9–13 November 2008.
Journal of the International AIDS Society, 11 (2008), pp. O6
[5.]
D.A. Rastegar, A.M. Knight, J.S. Monolakis.
Antiretroviral medication errors among hospitalized patients with HIV infection.
Clin Infect Dis, 43 (2006), pp. 933-938
[6.]
A. Walubo.
The role of cytochrome P450 in antiretroviral drug interactions.
Expert Opin Drug Metab Toxicol, 3 (2007), pp. 583-598
[7.]
K.C. Brown, S. Paul, A.D. Kashuba.
Drug interactions with new and investigational antiretrovirals.
Clin Pharmacokinet, 48 (2009), pp. 211-241
[8.]
A. Judith, M.D. Aberg.
Drug-Drug Interactions With newer antiretroviral agents.
Top HIV Med, 16 (2008), pp. 146-150
[9.]
J.J. Kiser.
Pharmacologic characteristics of investigational and recently approved agents for the treatment of HIV.
Curr Opin HIV AIDS, 3 (2008), pp. 330-341
[10.]
M.C. Long, J.R. King, E.P. Acosta.
Pharmacologic aspects of new antiretroviral drugs.
Curr HIV/AIDS Rep, 6 (2009), pp. 43-50
[11.]
L. Dickinson, S. Khoo, D. Back.
Pharmacokinetics and drug-drug interactions of antiretrovirals: An update.
Antiviral Research, 85 (2010), pp. 176-189
[12.]
S.M. Robertson, S.R. Penzak, A. Pau.
Drug interactions in the management of HIV infection: an update.
Expert Opin Pharmacother, 8 (2007), pp. 2947-2963
[13.]
J. Moltó, M. Valle, B. Clotet.
Pharmacological interactions with darunavir.
Enferm Infecc Microbiol Clin, 26 (2008), pp. 43-50
[14.]
D. Back, V. Sekar, R.M. Hoetelmans.
Darunavir: pharmacokinetics and drug interactions.
Antivir Ther, 13 (2008), pp. 1-13
[15.]
Ficha técnica de Prezista® (darunavir) [Internet document]. EMEA European Medicines Agency [accessed 2009 Jun 1]. Available from: http://www.emea.europa.eu/humandocs/PDFs/EPAR/prezista/emea-combined-h707es.pdf.
[16.]
Interaccioneshiv.com [internet datebase]. Hospital Clínic – IDIBAPS Barcelona [accessed 2009 June 1]. Available from: http://www.interaccioneshiv.com/Buscar.asp.
[18.]
J. Madruga, P. Cahn, R. Haubrich, et al.
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1 infected patients in DUET-1: 24-week results from a randomised, doubleblind, placebo-controlled trial.
[19.]
A. Lazzarin, T. Campbell, B. Clotet, et al.
Efficacy an safety of TMC125 (etravirine) in treatment-experienced HIV-1 infected patient in DUET-2: 24-week results from a randomised, doubleblind, placebo-controlled trial.
[20.]
Ficha técnica de Intelence® (etravirina) [Internet document] EMEA European Medicines Agency [accessed 2009 Jun 1]. Available from: http://www.emea.europa.eu/humandocs/PDFs/EPAR/intelence/emea-combined-h900es.pdf.
[21.]
V. Soriano, E. Poveda.
Pharmacokinetics, interactions and mechanism of action of maraviroc.
Enferm Infecc Microbiol Clin, 26 (2008), pp. 12-16
[22.]
J.M. Emmelkamp, J.K. Rockstroh.
CCR5 antagonists: comparison of efficacy, side effects, pharmacokinetics and interactions−review of the literature.
Eur J Med Res, 12 (2007), pp. 409-417
[23.]
Ficha técnica de Celsentri® (maraviroc) [Internet document]. EMEA European Medicines Agency [accessed 2009 Jun 1]. Available from: http://www.emea.europa.eu/humandocs/PDFs/EPAR/celsentri/emea-combined-h811es.pdf.
[24.]
Ficha técnica de Isentress® (raltegravir) [Internet document]. EMEA European Medicines Agency [accessed 2009 Jun 1]. Available from: http://www.emea.europa.eu/humandocs/PDFs/EPAR/isentress/emea-combined-h860es.pdf.
[25.]
R.W. Falcon, T.N. Kakuda.
Drug interactions between HIV protease inhibitors and acid-reducing agents.
Clin Pharmacokinet, 47 (2008), pp. 75-89
[26.]
S.M. McCabe, P.F. Smith, Q. Ma, G.D. Morse.
Drug interactions between proton pump inhibitors and antiretroviral drugs.
Expert Opin Drug Metab Toxicol, 3 (2007), pp. 197-207
[27.]
E. Pontali.
Interactions of antiretroviral drugs with anti-infectives and other antiretrovirals.
Chemotherapy, 53 (2007), pp. 26-29
[27.]
G.M. Ray.
Antiretroviral and statin drug-drug interactions.
Cardiol Rev, 17 (2009), pp. 44-47
[29.]
E.M. Yakiwchuk, M.M. Foisy, C.A. Hughes.
Complexity of interactions between voriconazole and antiretroviral agents.
Ann Pharmacother, 42 (2008), pp. 698-703

Part of the content of this article was presented to the “Jornadas de Actualización en el tratamiento de la infección por el VIH” (Conference on Updating HIV treatment), organised by the Government of Catalonia Health Department on 10 June in Barcelona.

Copyright © 2011. Sociedad Española de Farmacia Hospitalaria
Opciones de artículo
Herramientas